NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.90
+0.20 (1.07%)
At close: May 16, 2025, 4:00 PM
18.88
-0.02 (-0.11%)
After-hours: May 16, 2025, 4:05 PM EDT
NAMS Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for NAMS stock ranges from a low of $37 to a high of $52. The average analyst price target of $42.83 forecasts a 126.61% increase in the stock price over the next year.
Price Target: $42.83 (+126.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NAMS stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +111.64% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +122.22% | Apr 8, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $47 → $52 | Buy | Maintains | $47 → $52 | +175.13% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Maintains $46 → $42 | Strong Buy | Maintains | $46 → $42 | +122.22% | Feb 27, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +111.64% | Jan 28, 2025 |
Financial Forecast
Revenue This Year
18.86M
from 45.56M
Decreased by -58.62%
Revenue Next Year
17.03M
from 18.86M
Decreased by -9.66%
EPS This Year
-1.87
from -2.56
EPS Next Year
-1.92
from -1.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.2M | 61.2M | 264.0M | ||
| Avg | 18.9M | 17.0M | 127.3M | ||
| Low | n/a | n/a | 34.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -40.3% | 224.4% | 1,450.1% | ||
| Avg | -58.6% | -9.7% | 647.2% | ||
| Low | - | - | 101.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.31 | -0.43 | ||
| Avg | -1.87 | -1.92 | -1.49 | ||
| Low | -2.07 | -2.31 | -2.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.